Berry Genomics released its 2026 interim report, with net profit attributable to the parent company at negative 43.9479 million yuan, a loss expansion of 16.7053 million yuan compared with the same period last year. The company's total operating revenue was 447 million yuan, down 0.15% year-on-year; net cash outflow from operating activities was 102 million yuan. The latest asset-liability ratio was 32.76%, gross margin was 50.53%, ROE was negative 3.09%, and diluted earnings per share was negative 0.12 yuan.
Berry Genomics Co LtdNet loss widened to 43.95 million yuan, with revenue down and operating cash outflow.
